Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug

2 months ago 44

Soumya Eswaran

Fri, July 24, 2026 astatine 9:06 AM CDT 3 min read

ClearBridge Investments, a planetary equity manager, precocious published second-quarter 2026 commentary for its "Small Cap Growth Strategy". A transcript of the missive tin beryllium downloaded here. The Russell 2000 Growth Index accrued by 25.6% successful the 2nd quarter, marking its third-best quarterly show successful 2 decades. The rally was fueled by enthusiasm for AI, spot successful biotech, and gains successful high-beta, high-momentum stocks, amid rising retail trading enactment and constrictive enactment successful circumstantial themes. Despite a analyzable macroeconomic backdrop and ongoing debates astir the gait and interaction of AI infrastructure investments, enthusiasm for generational exertion investments remains robust. The Strategy achieved beardown implicit returns of implicit 21% (gross) during the 4th but lagged the Russell 2000 Growth benchmark owed to underperformance successful definite healthcare and fiscal stocks, bundle challenges, and constricted vulnerability to high-beta, high-momentum AI-related stocks. In addition, delight cheque the Strategy's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Clearbridge Small Cap Growth Strategy highlighted Axsome Therapeutics, Inc. (NASDAQ:AXSM) arsenic a recently added position. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is simply a biopharmaceutical company. On July 23, 2026, Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed astatine $241.53 per share, reflecting a marketplace capitalization of $12.43 billion. Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted a one-month instrumentality of -0.06%, portion its shares gained 139.54% implicit the past 52 weeks.

Clearbridge Small Cap Growth Strategy stated the pursuing regarding Axsome Therapeutics, Inc. (NASDAQ:AXSM) successful its Q2 2026 capitalist update:

"New thought procreation remained strong, with enactment elevated by the Russell rebalance. Axsome Therapeutics, Inc. (NASDAQ:AXSM), successful the wellness attraction sector, is simply a high-growth, commercial-stage biotechnology institution focused connected cardinal tense systems disorders. We judge that its cardinal drug, Auvelity, has a ample commercialized accidental with support successful Major Depressive Disorder and caller enlargement into Alzheimer's Disease Agitation."

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock successful 2025?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 55 hedge money portfolios held Axsome Therapeutics, Inc. (NASDAQ:AXSM) astatine the extremity of the archetypal quarter, up from 52 successful the erstwhile quarter. While we admit the imaginable of Axsome Therapeutics, Inc. (NASDAQ:AXSM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article